ArticleBritish journal of cancer2026

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.